Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 74Cyclophosphamide 49Cisplatin 46Nivolumab 36Paclitaxel 33Radiotherapy 32Carboplatin 31Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 22Bevacizumab 21Blood Specimen Collection 20Lenalidomide 19Etoposide 19Radiosurgery 18Magnetic Resonance Spectroscopy 18Leucovorin 18Fluorouracil 18Doxorubicin 18fludarabine 17Surveys and Questionnaires 17Rituximab 17Vincristine 16Oxaliplatin 16Cytarabine 16Ipilimumab 15palbociclib 14durvalumab 14Radiotherapy, Intensity-Modulated 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡